Skip to content

Study · Randomized controlled trial · n = 295 · 2008

2 results

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L

Lancet (London, England)7 Sept 2008Cited by 809 (Europe PMC)

PMID18782641 (opens in a new tab)DOI10.1016/s0140-6736(08)61206-4 (opens in a new tab)PepBankPUB-18782641
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, once-weekly exenatide reduced HbA1c more than twice-daily exenatide at 30 weeks.

    In plain wordsIn people with diabetes, weekly exenatide reduced A1c more than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 295

    Comparator
    Exenatide 10 mug twice daily
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 30 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.9%
    once weekly
    HbA1c change
    −1.5%
    twice daily
    95% CI lower
    −0.54%
    between treatments
    95% CI upper
    −0.12%
    between treatments

    Source sentences

    Summary
    At 30 weeks, the patients given exenatide once a week had significantly greater changes in HbA(1c) than those given exenatide twice a day (-1.9 [SE 0.1%] vs -1.5 [0.1%], 95% CI -0.54% to -0.12%; p=0.0023).
    2 context sentences
    Summary · context
    A 30-week, randomised, non-inferiority study compared a long-acting release formulation of exenatide 2 mg administered once weekly to 10 mug exenatide administered twice a day, in 295 patients with type 2 diabetes (haemoglobin A(1c) [HbA(1c)] 8.3% [SD 1.0], mean fasting plasma glucose 9 [SD 2] mmol/…
    Summary · context
    The patients were naive to drug therapy, or on one or more oral antidiabetic agents.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, more evaluable patients achieved HbA1c at or below 7.0% with weekly than twice-daily exenatide.

    In plain wordsIn people with diabetes, more participants reached A1c at or below 7.0% with weekly than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c at or below 7.0%
    Study

    n: not reported in source

    Comparator
    Exenatide 10 mug twice daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 30 weeksAs given in this study (human).

    Measurements

    Target attainment
    77%
    once weekly
    Target attainment
    61%
    twice daily

    Source sentences

    Summary
    A significantly greater proportion of patients receiving treatment once a week versus twice a day achieved target HbA(1c) levels of 7.0% or less (77%vs 61% of evaluable patients, p=0.0039).
    2 context sentences
    Summary · context
    A 30-week, randomised, non-inferiority study compared a long-acting release formulation of exenatide 2 mg administered once weekly to 10 mug exenatide administered twice a day, in 295 patients with type 2 diabetes (haemoglobin A(1c) [HbA(1c)] 8.3% [SD 1.0], mean fasting plasma glucose 9 [SD 2] mmol/…
    Summary · context
    The patients were naive to drug therapy, or on one or more oral antidiabetic agents.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial pageClinicalTrials.govUpdated 27 Jun 2025
CompletedPhase 4NCT02380521

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

University of Palermon = 60Jan 2015 to Nov 2016

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 8 Nov 2016
CompletedPhase 3Results postedNCT00308139

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AstraZenecan = 303Apr 2006 to Aug 2014

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 26 Aug 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.